Inspra Helps, Natrecor Useless for Heart Patients
By wchung | 25 Jun, 2026
There’s good news for millions of people with mild or moderate heart failure. Studies show that the Pfizer drug Inspra and an implanted device from Medtronic can boost survival and cut down on trips to the hospital.
However, another drug that has been used for nearly a decade, Johnson & Johnson’s Natrecor (NAY’-treh-kor), did little to help people with severe heart failure in a study aimed at resolving safety concerns. Doctors say the drug seems safe but does not markedly help shortness of breath or save lives.
The studies were presented Sunday at an American Heart Association conference in Chicago.
MARILYNN MARCHIONE, AP Medical Writer CHICAGO
© 2026 by Asian Media Group Inc.
Recent Articles
- Samsung to Invest $648 Billion, Mostly Outside Seoul Region
- Sanjay Mehrotra's Micron Overtakes Meta, Tesla in Market Value
- Lackluster S. Korea Suffers Embarrassing 0-1 Loss to S. Africa
- China's Carmakers See Canada as 'Practice Run’ for US Sales
- China's Z.ai Closes Frontier Gap with US AI Leaders
- China Targets Solar, Wind Power Producing Half of Electricity by 2030
- US Automotive Quality Increased Industrywide Last Year
- US Consumer Inflation Topped 4.0% in May As Consumer Spending Stays Strong
- Wealthy Nations Reap Huge Benefits from Immigration, Study Finds
- Oil Back to Pre-War Levels as Hormuz Traffic Rebounds As Iran Asserts Control
